Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChinese PLA General Hospital

About this trial

This is a randomized, open-label, multi-center clinical study aimed at evaluating the efficacy and safety of 12 weeks of nalfurafine hydrochloride administration in the treatment of pruritus in patients undergoing maintenance hemodialysis.

Eligibility criteria

Qualifiers

Age range of 18-80 years old (including both ends), male or female not limited.

Chronic renal failure patients who undergo stable dialysis for 3 months or more, receive regular hemodialysis 3 times a week, and are expected to have no significant changes in treatment or rapid changes in their condition during the clinical trial period.

Within one year prior to signing the informed consent form, the effectiveness of itch treatment (including topical medications such as moisturizers/moisturizers, systemic medications such as antihistamines or antiepileptic drugs, and non pharmacological treatments) was not satisfactory.

Those who are able to understand and comply with the research procedures and methods, voluntarily participate in this study, and sign a written informed consent form.

Disqualifiers

Given poor compliance with dialysis treatment, researchers believe that it may affect the effectiveness and safety of clinical studies.

Patients who plan to undergo kidney transplantation or other elective surgeries during the study period.

Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or glutamine transferase (GGT) levels exceeding the upper limit of normal (ULN) by 2 times, or total bilirubin levels exceeding the upper limit of normal (ULN) by 2 times during the screening period.

Skin itching is not caused by chronic kidney disease, including allergic skin diseases (atopic dermatitis, urticaria, eczema, drug rash, etc.), physical skin diseases (prickly heat, solar rash, etc.), infectious skin diseases (insect bite dermatitis, chickenpox, measles, pyoderma, tinea corporis, etc.), cholestatic liver disease, etc.

Trial design

Treatments tested in this trial

  • Nalfurafine Hydrochloride
  • Basic treatment

Treatment groups

150 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Chinese PLA General Hospital

Lead sponsor

The First Affiliated Hospital of Dalian Medical University

Collaborator

Beijing Friendship Hospital

Collaborator

The General Hospital of Northern Theater Command

Collaborator

Tianjin First Central Hospital

Collaborator

RenJi Hospital

Collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator

Xiangyang Central Hospital

Collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator

Jiangsu Taizhou People's Hospital

Collaborator

Qilu Hospital of Shandong University

Collaborator

First Affiliated Hospital Xi'an Jiaotong University

Collaborator

Zigong No.1 Peoples Hospital

Collaborator

Chengdu First People's Hospital

Collaborator

The People's Hospital of Leshan

Collaborator

The Third Affiliated Hospital of Wenzhou Medical University

Collaborator

Henan Provincial People's Hospital

Collaborator

Shanghai Changzheng Hospital

Collaborator

Daping Hospital of Army Medical University

Collaborator

First Affiliated Hospital of Wannan Medical College

Collaborator